| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
DB2313
(DB 2313) manufacturers
- DB2313
-
- $46.00
-
2026-07-14
- CAS:2170606-74-1
- Purity: 99.93%
- Supply Ability: 10g
|
| | DB2313
(DB 2313) Basic information |
| Product Name: | DB2313
(DB 2313) | | Synonyms: | DB2313
(DB 2313);DB2313;DB2313
（HCl）;1H-Benzimidazole-6-carboximidamide, 2,2'-[(2-fluoro-1,3-phenylene)bis(methyleneoxy-4,1-phenylene)]bis[N-(1-methylethyl)-;2,2'-((((2-Fluoro-1,3-phenylene)bis(methylene))bis(oxy))bis(4,1-phenylene))bis(N-isopropyl-1H-benzo[d]imidazole-6-carboximidamide);2-[4-({2-fluoro-3-[(4-{6-[N-(propan-2-yl)carbamimidoyl]-1H-1,3-benzodiazol-2-yl}phenoxy)methyl]phenyl}methoxy)phenyl]-N-(propan-2-yl)-1H-1,3-benzodiazole-6-carboximidamide;DB2313
DB2313.4HCl;2,2'-((((2-Fluoro-1,3-phenylene)bis(methylene))bis(oxy))bis(4,1-phenylene))bis(N-isopropyl-1H-benzo[d]imidazole-6-carboximidamide) | | CAS: | 2170606-74-1 | | MF: | C42H41FN8O2 | | MW: | 708.83 | | EINECS: | | | Product Categories: | | | Mol File: | 2170606-74-1.mol |  |
| | DB2313
(DB 2313) Chemical Properties |
| Boiling point | 880.9±75.0 °C(Predicted) | | density | 1.30±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 9.74±0.10(Predicted) | | color | Off-white to gray |
| | DB2313
(DB 2313) Usage And Synthesis |
| Uses | DB2313 is a potent inhibitor of transcription factor PU.1. DB2313 inhibits PU.1-dependent reporter gene transactivation with an IC50 of 5 μM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis in acute myeloid leukemia (AML) cells and has anticancer effects[1]. | | in vivo | DB2313 (17 mg/kg; i.p.; three times per week; for 3 weeks) treatment decreases leukemia progression and results in increased survival in mice[1]. | Animal Model: | NSG mice bearing sublethally irradiated (2.0 Gy) and injection with PU.1 URE–/– AML cells[1] | | Dosage: | 17 mg/kg | | Administration: | Intraperitoneal injection; three times per week; for 3 weeks | | Result: | Decreased tumor burden and resulted in increased survival. |
| | References | [1] Iléana Antony-Debré, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest. 2017 Dec 1;127(12):4297-4313. DOI:10.1172/JCI92504
[2] Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner. Mol Ther Nucleic Acids. 2022;27:699-717. DOI:10.1016/j.omtn.2021.12.035 |
| | DB2313
(DB 2313) Preparation Products And Raw materials |
|